Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 9/20 | 0.63 |
| ▸ | ST3GAL1 | Q11201 | 2/20 | 0.63 |
| ▸ | ST3GAL3 | Q11203 | 1/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801929 | 0.89 | ST6GAL1 (0.79) | ST6GAL1ST3GAL1ST3GAL3GRIN1GRIN2B | |
| SCHEMBL18576098 | 0.73 | ST6GAL1 (1.00) | ST6GAL1ST3GAL1ST3GAL3 | |
| SCHEMBL29354917 | 0.73 | ST6GAL1 (1.00) | ST6GAL1ST3GAL1ST3GAL3 | |
| SCHEMBL22989853 | 0.71 | GRIN1 (0.66) | ST6GAL1GRIN1GRIN2BGRIN2DGRIN2A | |
| SCHEMBL7354723 | 0.71 | GRIN1 (0.70) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL7420800 | 0.71 | GRIN1 (0.70) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL7420797 | 0.71 | GRIN1 (0.70) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL18346659 | 0.71 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL18346660 | 0.71 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL22989911 | 0.71 | GRIN1 (0.62) | ST6GAL1GRIN1GRIN2BGRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071453-A1 | STEROIDE ANIONIC COMPOUNDS, METHOD OF THEIR PRODUCTION, USAGE AND PHARMACEUTICAL PREPARATION INVOLVING THEM | PSYCHIATRICKE CENTRUM PRAHA (CZ) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071453-A1 | STEROIDE ANIONIC COMPOUNDS, METHOD OF THEIR PRODUCTION, USAGE AND PHARMACEUTICAL PREPARATION INVOLVING THEM | GRIN2A, GRIN2B, GRIN1 | ST6GAL1 1424/4885ST3GAL1 3314/4885ST3GAL3 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.